Exelixis

Exelixis

Yahoo Finance • 7 days ago

Exelixis Non-GAAP EPS of $0.94 beats by $0.04, revenue of $658.7M beats by $10.19M

* Exelixis press release [https://seekingalpha.com/pr/20706590-exelixis-announces-third-quarter-2026-financial-results-and-provides-corporate-update] (EXEL [https://seekingalpha.com/symbol/EXEL]): Q3 Non-GAAP EPS of $0.94 beats by $0.04.... Full story

Yahoo Finance • 13 days ago

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth. Continue Reading... Full story

Yahoo Finance • 14 days ago

BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.

Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth. Continue Reading... Full story

Yahoo Finance • 22 days ago

Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight

Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch. Continue Reading... Full story

Yahoo Finance • 22 days ago

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity InsiderNews Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United Sta... Full story

Yahoo Finance • 23 days ago

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Akari Therapeutics Plc Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value Mr. Vat-Ho brings hig... Full story

Yahoo Finance • last month

These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.

A few IBD 50 stocks are showing unusually narrow trading. Continue Reading... Full story

Yahoo Finance • last month

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks

Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select... Full story

Yahoo Finance • 2 months ago

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Key Points Interested in Exelixis, Inc.? Here are five stocks we like better. CABOMETYX growth remains a focus, with Exelixis targeting a potential $3 billion franchise through deeper penetration in renal cell carcinoma and neuroendocrine... Full story

Yahoo Finance • 2 months ago

Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay

Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment. Continue Reading... Full story

Yahoo Finance • 2 months ago

ServiceNow Leads Five Stocks To Watch Near Buy Points

Meanwhile, several stocks showed bullish signs, including software giant ServiceNow. Digital bank Dave Inc., commodities trading platform Marex Group, senior living REIT Welltower and cancer treatment developer Exelixis round out the list... Full story

Yahoo Finance • 2 months ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Why This Top-Ranked IBD 50 Stock Just Plummeted On Its Earnings

Exelixis stock toppled late Wednesday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations. Continue Reading... Full story

Yahoo Finance • 3 months ago

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders.  Th... Full story

Yahoo Finance • 4 months ago

Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination

(RTTNews) - Exelixis, Inc. (EXEL) on Monday reported final analysis results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with Roche's Tecentriq versus regorafenib in previously treated non-microsatellite insta... Full story

Yahoo Finance • 5 months ago

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story

Yahoo Finance • 5 months ago

Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock

We just covered the 12 Best Stocks to Invest In According to Jim Simons’ Renaissance Technologies and Exelixis, Inc. (NASDAQ:EXEL) ranks 7th on this list. Exelixis, Inc. (NASDAQ:EXEL) is another long-term holding in the 13F portfolio of R... Full story

Yahoo Finance • 6 months ago

Assessing Exelixis (EXEL) Valuation After Merck Zanzalintinib Keytruda Colorectal Cancer Collaboration

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Exelixis (EXEL) is back in the spotlight after announcing a clinical development collaboration wit... Full story

Yahoo Finance • 6 months ago

Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization

Earnings Call Insights: Exelixis (EXEL) Q1 2026 MANAGEMENT VIEW * Michael Morrissey (CEO, President & Director) said the company’s strategy is “to build a multi-franchise business in solid tumor oncology focused on GU and GI histologie... Full story

Yahoo Finance • 6 months ago

Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma

Company Logo The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs, rare tumors originating... Full story